Current clinical consensus reflects the following: Research findings are preliminary and insufficient to guide treatment decisions No regulatory approval exists for using GLP-1s in addiction treatment Early signals do not outweigh the lack of long-term outcome data Instead, clinicians continue to recommend established, evidence-based approaches, including: Behavioral therapies tailored to substance use disorders Medication-assisted treatment when medically indicated Comprehensive psychosocial support and relapse-prevention planning Comprehensive assessment remains a cornerstone of safe and effective care
The role of the autonomic nervous system in the pathophysiology of obesity
Activating GIP receptors is thought to enhance the effects of GLP-1 when these two actions are combined
Zepbound is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm
Patients using Semaglutide GLP-1 often experience greater weight loss compared to those on placebo, with some studies reporting up to 15% reduction in body weight
Muscle, especially axial muscle, is essential for posture, physical function and overall well-being
